tptkas
- New management in place with proven track record of bringing several anti cancer drugs to commercial markets.<br /><br />2) $50 mln deal with GPC Biotech for Satraplatin that is a phase 3 drug<br /><br />3) Insiders buying heavily<br /><br />4) Several drugs in pipeline with billions of dollars potential.<br /><br />5) Float is tiny - under 3 mln shares<br /><br />6) Market capital is very low - under $4 mln<br /><br />7) Float mostly in hands of investors in for long term<br /><br />8) Entry into Generic drugs business which has US market potential of north of $15 bln/yr<br /><br />9) Attractive buyout candidate<br /><br />10) Strategic investment & deal with India's leading Pharmaceuticals company JB Pharma & Chem<br /><br />11) Company has spend over $150 millions in research over the last 10+ years<br /><br />